Table 2.

Univariate analysis of patient survival.

Variables		HR (95% CI)	P-value
d-Dimer	0.61 ± 0.49 mg/L	1.55 (1.23, 1.95)	0.0002
Age (years)
≤60	370 (56.84%)	1
>60	281 (43.16%)	1.29 (1.03, 1.60)	0.0238
Sex
Male	433 (66.51%)	1
Female	218 (33.49%)	0.76 (0.60, 0.96)	0.0225
Smoking history
Never smoked	328 (50.38%)	1
Previous smoker	234 (35.94%)	1.33 (1.05, 1.68)	0.0197
Current smoker	89 (13.67%)	1.60 (1.15, 2.22)	0.0051
ECOG-PS
<2	595 (91.40%)	1
≥2	56 (8.60%)	1.38 (0.95, 2.01)	0.0867
Clinical stage
IIIB	98 (15.05%)	1
IV	553 (84.95%)	1.46 (1.06, 2.00)	0.0191
Histological diagnosis
Adenocarcinoma	504 (77.42%)	1
Squamous cell carcinoma	126 (19.35%)	1.30 (0.99, 1.71)	0.0565
Others	21 (3.23%)	1.76 (1.01, 3.07)	0.0478
Degree of differentiation
Poorly differentiated	242 (37.17%)	1
Moderately differentiated	121 (18.59%)	0.86 (0.64, 1.15)	0.3088
Well-differentiated	136 (20.89%)	0.30 (0.22, 0.42)	<0.0001
Unknown	152 (23.35%)	1.96 (1.42, 2.70)	<0.0001
Mutation status
No	473 (72.66%)	1
EGFR/ALK/ROS1 mutation	178 (27.34%)	0.42 (0.31, 0.56)	<0.0001
Sum of metastasis organs
≤2	329 (50.54%)	1
>2	322 (49.46%)	1.34 (1.08, 1.67)	0.0080
Sum of treatment lines
<2	424 (65.13%)	1
≥2	227 (34.87%)	0.78 (0.63, 0.98)	0.0320
Treatment approach
None	89 (13.67%)	1
Chemotherapy	320 (49.16%)	0.63 (0.46, 0.87)	0.0043
Tyrosine kinase inhibitors	172 (26.42%)	0.49 (0.34, 0.70)	<0.0001
Other	70 (10.75%)	0.51 (0.31, 0.81)	0.0047

Data are presented as the mean ± SD or n (%).

HR, hazard ratio; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; ROS1, c-ros oncogene 1 kinase.